Law360, New York (September 06, 2005, 12:00 AM ET) -- A federal appeals court has reinstated part of an antitrust challenge to a deal between Irish drug maker Elan and Skyepharma over a generic version of the non-steroidal anti-inflammatory drug Naprelan (naproxen sodium).
The U.S. Court of Appeals for the 11th Circuit agreed with a Florida district court that the Noerr-Pennington doctrine immunized Elan from an antitrust suit based on generic maker Andrx’s allegations that Elan filed a sham lawsuit to protect its monopoly on the market for a controlled release naproxen medication.
However, the court...
Elan, Andrx Antitrust Battle Over Naproxen Deal Heads Back To District Court
To view the full article, take a free trial now.
